Clinical trials: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.
- Trial name
- NCT04658004
- Testing
- NKG2D CAR T-cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to…
- Conditions
- Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Trial name
- NCT03816319
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Acute, AML, Adult
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
- Conditions
- Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes
- Trial name
- NCT04482894
- Testing
- Palliative Care Visits
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Virginia
AML
NK Cell Therapy for AML
This is a single-arm, open-label, non-randomized, multiple-dose, phase 1 dose escalation study evaluating the safety, efficacy and PK of CT101a in patients with relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT05256277
- Testing
- CT101a
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhejiang University
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
This study is to determine the safety and preliminary efficacy of sabatolimab in combination with magrolimab and azacitidine in adult participants with 1L unfit Acute Myeloid Leukemia (AML) or with 1L higher risk Myelodysplastic…
- Trial name
- NCT05367401
- Testing
- Sabatolimab, Magrolimab, Azacitidine
- Sponsor
- Novartis Pharmaceuticals
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of MEK162 that can be given to patients with advanced leukemia. This is an investigational study.
- Trial name
- NCT02089230
- Testing
- MEK 162
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic natural killer(NK) cells in subjects with refractory or relapsed AML after allogeneic hematopoietic stem cell…
- Trial name
- NCT05744440
- Testing
- allogenic NK cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xuzhou Medical University
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma
- Trial name
- NCT04553692
- Testing
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars)
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 272 people
- Sponsor
- IGM Biosciences, Inc.
Acute Myeloid Leukemia (AML)
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
This is a randomized，multicenter, open-label Phase III, clinical study to confirm the efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated Acute Myeloid Leukemia（AML）compared to salvage…
- Trial name
- ALIVE (NCT04716114)
- Testing
- SKLB1028, Salvage Chemotherapy
- Where
- China
- Volunteers
- 315 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
The purpose of this study is to determine the safety and efficacy of DFP-10917 given via continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).
- Trial name
- NCT01702155
- Testing
- DFP-10917
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Delta-Fly Pharma, Inc.
Acute Myeloid Leukemia
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels (800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT01349049
- Testing
- PLX3397
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Daiichi Sankyo
Relapsed or Refractory Acute Myeloid Leukemia
CD123 Redirected Autologous T Cells for AML
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR…
- Trial name
- NCT02623582
- Testing
- Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Acute Myeloid Leukemia
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Selinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial…
- Trial name
- NCT02416908
- Testing
- Selinexor, Cladribine, G-CSF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Relapsed or Refractory Acute Myeloid Leukemia
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
- Trial name
- NCT05726110
- Testing
- Selinexor, Homoharringtonine, Daunorubicin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Bethune Hospital
AML, Adult
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
This is a non-randomized prospective open-label single-arm clinical phase I trial investigating dose finding, feasibility and safety of the combined treatment of HDM201 and midostaurin in patients with relapsed/refractory acute…
- Trial name
- HDMM (NCT04496999)
- Testing
- HDM201, Midostaurin
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00634244
- Testing
- alvocidib, mitoxantrone hydrochloride, carboplatin
- Where
- 20 sites in United States, Israel
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of a enasidenib in combination with cobimetinib in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment…
- Trial name
- NCT05441514
- Testing
- Cobimetinib, Enasidenib Mesylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia
Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
This phase Ib trial studies the toxicity and dosing of venetoclax in combination with selinexor, and how well the combination works in treatment of patients with high risk hematologic malignancies such as diffuse large B-cell…
- Conditions
- Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT03955783
- Testing
- Venetoclax, Selinexor
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- Sanjay Mohan
Leukemia, Myelodysplastic Syndromes
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. UCN-01 may make cancer cells more sensitive to cytarabine.
- Trial name
- NCT00004263
- Testing
- 7-hydroxystaurosporine (UCN-01), Cytarabine (Ara-C)
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center